The main Investigator overseeing Stage II.

Biomoda to start multisite Stage III clinical trials of CyPath assay Medical diagnostics company Biomoda, Inc. Thomas Bauer, the main Investigator overseeing Stage II, has decided to continue in the same function for our Stage III trials . Dr. Bauer is more popular among the top lung cancers experts in the field, and we are privileged to end up being dealing with him. Cousins stated that Biomoda can be finalizing the protocol because of its Stage III trials for submission to an Institutional Review Plank in early 2010. IRB review protects study subjects by building sure the scholarly research process adheres to U.S. Food and Medication Administration and U.S. Section of Health insurance and Human Services rules, that risks to individuals are appropriate and minimized in light of the feasible benefits, that the educated consent document is certainly accurate, and that the study is conducted within an ethical manner.